Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions

JACC: Cardiovascular Interventions

Volumn 10, Issue 5, 2017, Pages 425-437

  Capodanno, Davide ^a   Angiolillo, Dominick J ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

bioresorbable vascular scaffolds; dual antiplatelet therapy

Indexed keywords

ANTITHROMBOCYTIC AGENT;

BIORESORBABLE VASCULAR SCAFFOLD; CORONARY STENT; DRUG ELUTING STENT; HUMAN; IMPLANTATION; INCIDENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; TREATMENT DURATION; ADVERSE EFFECTS; BIODEGRADABLE IMPLANT; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICES; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROSTHESIS DESIGN; RISK ASSESSMENT; STENT; TIME FACTOR; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85014567085     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.12.279     Document Type: Review

References (65)

1. 1 Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS Guidelines on Myocardial Revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
2. 2 Levine, G.N., Bates, E.R., Bittl, J.A., et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
3. 3 Franchi, F., Angiolillo, D.J., Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 12 (2015), 30–47.
4. 4 Kang, S.H., Chae, I.H., Park, J.J., et al. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. J Am Coll Cardiol Intv 9 (2016), 1203–1212.
5. 5 Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
6. 6 Roffi, M., Patrono, C., Collet, J.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 267–315.
7. 7 Kereiakes, D.J., Onuma, Y., Serruys, P.W., Stone, G.W., Bioresorbable vascular scaffolds for coronary revascularization. Circulation 134 (2016), 168–182.
8. 8 Farooq, V., Serruys, P.W., Heo, J.H., et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. J Am Coll Cardiol Intv 6 (2013), 523–532.
9. 9 Tamburino, C., Latib, A., van Geuns, R.J., et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention 11 (2015), 45–52.
10. 10 Gomez-Lara, J., Radu, M., Brugaletta, S., et al. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. J Am Coll Cardiol Intv 4 (2011), 992–1001.
11. 11 Raber, L., Brugaletta, S., Yamaji, K., et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol 66 (2015), 1901–1914.
12. 12 Puricel, S., Arroyo, D., Corpataux, N., et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 65 (2015), 791–801.
13. 13 Kimura, T., Kozuma, K., Tanabe, K., et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 36 (2015), 3332–3342.
14. 14 Gao, R., Yang, Y., Han, Y., et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol 66 (2015), 2298–2309.
15. 15 Ellis, S.G., Kereiakes, D.J., Metzger, D.C., et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 373 (2015), 1905–1915.
16. 16 Lipinski, M.J., Escarcega, R.O., Baker, N.C., et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis. J Am Coll Cardiol Intv 9 (2016), 12–24.
17. 17 Capodanno, D., Gori, T., Nef, H., et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 10 (2015), 1144–1153.
18. 18 Ishibashi, Y., Nakatani, S., Onuma, Y., Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients. EuroIntervention 11 (2015), e1–e2.
19. 19 Stone, G.W., Gao, R., Kimura, T., et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 387 (2016), 1277–1289.
20. 20 Collet, C., Asano, T., Sotomi, Y., et al. Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studies. Minerva Cardioangiol 65 (2016), 32–51.
21. 21 Karanasos, A., Van Mieghem, N., van Ditzhuijzen, N., et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv, 8, 2015, e002369.
22. 22 Puricel, S., Cuculi, F., Weissner, M., et al. Bioresorbable coronary scaffold thrombosis: Multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol 67 (2016), 921–931.
23. 23 Chevalier, B., Onuma, Y., van Boven, A.J., et al. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention 12 (2016), 1102–1107.
24. 24 Onuma, Y., Sotomi, Y., Shiomi, H., et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention 12 (2016), 1090–1101.
25. 25 Serruys, P.W., Chevalier, B., Sotomi, Y., et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 388 (2016), 2479–2491.
26. 26 Cassese, S., Byrne, R.A., Ndrepepa, G., et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 387 (2016), 537–544.
27. 27 Giblett, J.P., Brown, A.J., Keevil, H., Jaworski, C., Hoole, S.P., West, N.E., Implantation of bioresorbable vascular scaffolds following acute coronary syndrome is associated with reduced early neointimal growth and strut coverage. EuroIntervention 12 (2016), 724–733.
28. 28 Felix, C.M., Fam, J.M., Diletti, R., et al. Mid- to long-term clinical outcomes of patients treated with the everolimus-eluting bioresorbable vascular scaffold: the BVS Expand Registry. J Am Coll Cardiol Intv 9 (2016), 1652–1663.
29. 29 Chan, C.Y., Wu, E.B., Yan, B.P., Very late bioresorbable scaffold thrombosis caused by intraluminal scaffold dismantling. J Am Coll Cardiol Intv 9 (2016), 1844–1847.
30. 30 Azzalini, L., Al-Hawwas, M., L'Allier, P.L., Very late bioresorbable vascular scaffold thrombosis: a new clinical entity. EuroIntervention 11 (2015), e1–e2.
31. 31 Yahagi, K., Virmani, R., Kesavamoorthy, B., Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy. Cardiovasc Interv Ther 32 (2017), 53–55.
32. 32 Cortese, B., Piraino, D., Ielasi, A., Steffenino, G., Orrego, P.S., Very late bioresorbable vascular scaffold thrombosis due to late device recoil. Int J Cardiol 189 (2015), 132–133.
33. 33 Rumiz Gonzalez, E., Vilar Herrero, J.V., Berenguer Jofresa, A., Very late thrombosis of a bioresorbable scaffold. Rev Esp Cardiol (Engl Ed), 69, 2016, 211.
34. 34 Timmers, L., Stella, P.R., Agostoni, P., Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy. Eur Heart J, 36, 2015, 393.
35. 35 Meincke, F., Spangenberg, T., Heeger, C.H., Bergmann, M.W., Kuck, K.H., Ghanem, A., Very late scaffold thrombosis due to insufficient strut apposition. J Am Coll Cardiol Intv 8 (2015), 1768–1769.
36. 36 Giacchi, M., Pedrazzini, G., Moccetti, T., Moccetti, M., A very late thrombosis in a bioresorbable vascular scaffold. EuroIntervention, 11, 2015, e1.
37. 37 Ielasi, A., Cortese, B., Steffenino, G., Late structural discontinuity as a possible cause of very late everolimus-eluting bioresorbable scaffold thrombosis. J Am Coll Cardiol Intv 8 (2015), e171–e172.
38. 38 Sato, T., Abdel-Wahab, M., Richardt, G., Very late thrombosis observed on optical coherence tomography 22 months after the implantation of a polymer-based bioresorbable vascular scaffold. Eur Heart J, 36, 2015, 1273.
39. 39 Karanasos, A., van Geuns, R.J., Zijlstra, F., Regar, E., Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy. Eur Heart J, 35, 2014, 1781.
40. 40 Arroyo, D., Cook, S., Puricel, S., Mechanisms of late and very late bioresorbable vascular scaffold thrombosis: is it only about flow?. J Am Coll Cardiol 67 (2016), 1259–1260.
41. 41 Capodanno, D., Joner, M., Zimarino, M., What about the risk of thrombosis with bioresorbable scaffolds?. EuroIntervention 11:Suppl V (2015), V181–V184.
42. 42 Kolandaivelu, K., Swaminathan, R., Gibson, W.J., et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123 (2011), 1400–1409.
43. 43 Serruys, P.W., Chevalier, B., Dudek, D., et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385 (2015), 43–54.
44. 44 Tello-Montoliu, A., Rivera, J., Hernandez-Romero, D., et al. Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. Platelets 27 (2016), 777–783.
45. 45 Gross, L., Sibbing, D., Eickhoff, M., et al. Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity. Platelets 27 (2016), 446–451.
46. 46 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371 (2008), 1353–1363.
47. 47 Steg, P.G., Harrington, R.A., Emanuelsson, H., et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 128 (2013), 1055–1065.
48. 48 Hochholzer, W., Amann, M., Titov, A., et al. Randomized comparison of different thienopyridine loading strategies in patients undergoing elective coronary intervention: the ExcelsiorLOAD trial. J Am Coll Cardiol Intv 9 (2016), 219–227.
49. 49 Cuisset, T., Cayla, G., Quilici, J., et al. Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. Int J Cardiol 168 (2013), 2988–2989.
50. 50 Angiolillo, D.J., Franchi, F., Waksman, R., et al. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI. J Am Coll Cardiol 67 (2016), 603–613.
51. 51 Capodanno, D., Angiolillo, D.J., Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv, 8, 2015, e002301.
52. 52 Fan, W., Plent, S., Prats, J., Deliargyris, E.N., Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol 117 (2016), 1439–1443.
53. 53 Widimsky, P., Motovska, Z., Simek, S., et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 29 (2008), 1495–1503.
54. 54 Montalescot, G., Bolognese, L., Dudek, D., et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369 (2013), 999–1010.
55. 55 Montalescot, G., van 't Hof, A.W., Lapostolle, F., et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371 (2014), 1016–1027.
56. 56 Montalescot, G., Sechtem, U., Achenbach, S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34 (2013), 2949–3003.
57. 57 Cortese, B., Buccheri, D., Stefanini, G.G., Mehran, R., The contemporary pulse of bioresorbable-scaffold thrombosis among expert operators. J Am Coll Cardiol 67 (2016), 2905–2906.
58. 58 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
59. 59 Capodanno, D., Angiolillo, D.J., Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv 7 (2014), 113–124.
60. 60 Parodi, G., Valenti, R., Bellandi, B., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61 (2013), 1601–1606.
61. 61 Parodi, G., Bellandi, B., Xanthopoulou, I., et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv, 8, 2015, e001593.
62. 62 Kubica, J., Adamski, P., Ostrowska, M., et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 37 (2016), 245–252.
63. 63 Rollini, F., Franchi, F., Hu, J., et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol 67 (2016), 1994–2004.
64. 64 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
65. 65 Smith, S.C. Jr., Benjamin, E.J., Bonow, R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 58 (2011), 2432–2446.